Bridgebio Pharma logo

Bridgebio Pharma Share Price Today

(NASDAQ: BBIO)

Bridgebio Pharma share price is $33.75 & ₹2,919.88 as on 20 Mar 2025, 2.30 'hrs' IST

$33.75

1.56

(4.85%)

Market is closed - opens 7 PM, 20 Mar 2025

View live Bridgebio Pharma share price in Dollar and Rupees. Guide to invest in Bridgebio Pharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Bridgebio Pharma, along with analyst recommendations, forecasts, and comprehensive financials.

Bridgebio Pharma share price movements

  • Today's Low: $32.04
    Today's High: $33.81

    Day's Volatility :5.24%

  • 52 Weeks Low: $21.62
    52 Weeks High: $39.47

    52 Weeks Volatility :45.22%

Bridgebio Pharma (BBIO) Returns

PeriodBridgebio Pharma IncSector (Health Care)Index (Russel 2000)
3 Months
28.77%
-9999999.0%
0.0%
6 Months
25.79%
-9999999.0%
0.0%
1 Year
17.88%
-9999999.0%
0.0%
3 Years
223.28%
-9999999.0%
-15.2%

Bridgebio Pharma (BBIO) Key Statistics

in dollars & INR

Previous Close
$32.19
Open
$32.24
Today's High
$33.81
Today's Low
$32.04
Market Capitalization
$6.4B
Today's Volume
$2.0M
52 Week High
$39.47
52 Week Low
$21.62
Revenue TTM
$221.9M
EBITDA
$-554.8M
Earnings Per Share (EPS)
$-3.02
Profit Margin
-241.44%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-1789.67%

How to invest in Bridgebio Pharma Stock (BBIO) from India?

It is very easy for Indian residents to invest directly in Bridgebio Pharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bridgebio Pharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bridgebio Pharma or BBIO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bridgebio Pharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bridgebio Pharma shares which would translate to 0.026 fractional shares of Bridgebio Pharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Bridgebio Pharma, in just a few clicks!

Returns in Bridgebio Pharma (BBIO) for Indian investors in Rupees

The Bridgebio Pharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Bridgebio Pharma investment value today

Current value as on today

₹1,21,951

Returns

₹21,951

(+21.95%)

Returns from Bridgebio Pharma Stock

₹17,883 (+17.88%)

Dollar Returns

₹4,068 (+4.07%)

Indian investors sentiment towards Bridgebio Pharma (BBIO)

-16%

Period: Feb 17, 2025 to Mar 19, 2025. Change in 30 Days versus previous period

Search interest for Bridgebio Pharma Stock from India on INDmoney has decreased by -16% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Bridgebio Pharma

  • Kohlberg Kravis Roberts & Co LP

    13.28%

  • Viking Global Investors LP

    13.21%

  • Vanguard Group Inc

    7.93%

  • BlackRock Inc

    7.21%

  • State Street Corp

    3.25%

  • Aisling Capital Management LP

    3.19%

Analyst Recommendation on Bridgebio Pharma

Buy

    85%Buy

    15%Hold

    0%Sell

Based on 20 Wall street analysts offering stock ratings for Bridgebio Pharma(by analysts ranked 0 to 5 stars)

Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
17
17
16
Hold
3
3
3
Sell
0
0
0

Analyst Forecast on Bridgebio Pharma Stock (BBIO)

What analysts predicted

Upside of 58.52%

Target:

$53.50

Current:

$33.75

Insights on Bridgebio Pharma Stock (Ticker Symbol: BBIO)

  • Price Movement

    In the last 3 months, BBIO stock has moved up by 27.4%
  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.16M → 5.88M (in $), with an average increase of 37.1% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -35.21M → -265.05M (in $), with an average decrease of 97.6% per quarter
  • BBIO vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 71.3% return, outperforming this stock by 53.4%
  • Price to Sales

    ForBBIO every $1 of sales, investors are willing to pay $28.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.4 for every $1 of sales.

Bridgebio Pharma Technicals Summary

Sell

Neutral

Buy

Bridgebio Pharma is currently in a neutral trading position according to technical analysis indicators.

Bridgebio Pharma (BBIO) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bridgebio Pharma Inc logo
-4.9%
25.79%
17.88%
223.28%
39.52%
Alnylam Pharmaceuticals, Inc. logo
1.38%
-8.28%
71.25%
56.03%
155.84%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bridgebio Pharma Inc logo
NA
NA
NA
-3.74
-17.9
-0.48
NA
-7.72
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.52
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bridgebio Pharma Inc logo
Buy
$6.4B
39.52%
NA
-241.44%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.6B
155.84%
NA
-12.37%

Bridgebio Pharma Dividend announcements

  • Bridgebio Pharma Earnings

    Bridgebio Pharma’s price-to-earnings ratio stands at None

About Bridgebio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Organization
Bridgebio Pharma
Employees
725
CEO
Dr. Neil Kumar Ph.D.
Industry
Health Technology

Management People of Bridgebio Pharma

NameTitle
Dr. Neil Kumar Ph.D.
Co-Founder, CEO & Director
Dr. Charles J. Homcy M.D.
Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director
Dr. Frank P. McCormick Ph.D.
Co-Founder, Chairman of Oncology & Director

Important FAQs about investing in BBIO Stock from India :

What is Bridgebio Pharma share price today?

Bridgebio Pharma share price today stands at $33.75, Open: $32.24 ; Previous Close: $32.19 ; High: $33.81 ; Low: $32.04 ; 52 Week High: $39.47 ; 52 Week Low: $21.62.

The stock opens at $32.24, after a previous close of $32.19. The stock reached a daily high of $33.81 and a low of $32.04, with a 52-week high of $39.47 and a 52-week low of $21.62.

Can Indians buy Bridgebio Pharma shares?

Yes, Indians can invest in the Bridgebio Pharma (BBIO) from India.

With INDmoney, you can buy Bridgebio Pharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Bridgebio Pharma at zero transaction cost.

How can I buy Bridgebio Pharma shares from India?

It is very easy to buy Bridgebio Pharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bridgebio Pharma (BBIO) be purchased?

Yes, you can buy fractional shares of Bridgebio Pharma with INDmoney app.

What are the documents required to start investing in Bridgebio Pharma stocks?

To start investing in Bridgebio Pharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Bridgebio Pharma Stock (BBIO)?

Today’s highest price of Bridgebio Pharma (BBIO) is $33.81.

Today’s lowest price of Bridgebio Pharma (BBIO) is $32.04.

What is today's market capitalisation of Bridgebio Pharma?

Today's market capitalisation of Bridgebio Pharma BBIO is 6.4B

What is the 52 Week High and Low Range of Bridgebio Pharma Stock (BBIO)?

  • 52 Week High

    $39.47

  • 52 Week Low

    $21.62

What are the historical returns of Bridgebio Pharma (BBIO)?

  • 1 Month Returns

    -4.9%

  • 3 Months Returns

    25.79%

  • 1 Year Returns

    17.88%

  • 5 Years Returns

    39.52%

Who is the Chief Executive Officer (CEO) of Bridgebio Pharma ?

Dr. Neil Kumar Ph.D. is the current Chief Executive Officer (CEO) of Bridgebio Pharma.